DOCSLIB.ORG

Roche Investor Day 2012 Workshop Gred

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Roche Investor Day 2012 Workshop Gred gRED: Highlights with focus on Inflammation Richard H. Scheller Head of gRED Roche Group Unique diversity of approaches Independent centers for research Academia & Worldwide execution industry and early development Global Product gRED Development Over 150 pRED Manufacturing partners Chugai Commercialisation Roche Diagnostics 2 Genentech Research and Early Development Genentech Research & Early Development aspires to make fundamental scientific discoveries and to develop these discoveries into first and best in class therapeutics that provide unique benefit to patients Genentech founded: 1976 Integrated with Roche: 2009 Genentech Research and Early Development (gRED) is established as independent unit within the Roche Group gRED Business Divisions: Research, Early Development, Portfolio Management and Operations, gPartnering Therapeutic Areas: Oncology, Immunology, Metabolism, Neuroscience, Infectious Disease Pipeline: 39 NMEs in Early development to Phase 2 Science gRED Employees: ~ 2,000 Genentech named on Fortune‘s “100 Best Companies to Work For“ – thirteen consecutive year on the list Cell 3 The Research Leadership Team Michael Varney Andy Chan Senior Vice President Senior Vice President Small Molecule Drug Discovery Biology Rick Brown Vice President Immunology & Infectious Diseases Bruce Roth Vice President Discovery Chemistry Melissa Starovasnik Vice President Res Ops & Structural Biology Fred de Sauvage Vice President – Molecular Biology Vishva Dixit Vice President Early Discovery Research Ira Mellman Morgan Sheng Vice President – Oncology Vice President – Neuroscience 4 Proven track record of scientific excellence Genentech publications 600 Total Cell, Science, Nature 500 479 406 400 376 306 289 288 303 291 292 280 284 272 285 300 243 253 248 248 235 222 204 205 205 183 193 200 165 180 166 133 90 100 100 63 41 16 3 7 8 161622192916221212101611128 7 7 6 104 3 4 9 4 9 107 1117125 0 1980 1982 1984 1986 1988 1990 1992 1994 1996 1998 2000 2002 2004 2006 2008 2010 2012 12 papers were published in Cell, Science and US patents issued to Genentech in the last 10 Nature in 2011 years 300 275 221 200 137 123 85 100 70 76 74 67 70 79 0 2001 2003 2005 2007 2009 2011 5 gRED portfolio governance Research Review Committee (RRC) Early Stage Portfolio Committee (ESPC) • Sponsor: Richard Scheller, Ph.D. • Sponsor: Richard Scheller, Ph.D. • Alternate Chairs: • Alternate Chairs: • Andy Chan, M.D., Ph.D. • Sean Bohen, M.D., Ph.D. • Ira Mellman, Ph.D. • Mike Varney, Ph.D. ED Phase 1 Phase 2 LIP Decision ESR LSR ED Go Go Ready Go Go Go ready Points Discovery Early Stage Late Stage Early Phase Phase 1 Phase 2 Phase 3 Research Research Research Development Governance ESPC LSPC / CEC RRC Scientific Late Stage DRC review DRC Stratify/ Diagnostics Formulate diagnostic hypothesis Test diagnostic hypothesis validate 6 Our approach to discovery research Understanding disease biology is crucial in developing an effective treatment Homogeneous diseases Defined underlying molecular defects manifesting in a unique set of symptoms Example: Erivedge in Basal Cell Carcinoma (BCC) Heterogeneous diseases The majority of diseases caused by multiple defects that manifest as similar clinical syndromes. Currently, we classify and attempt to treat them as a single, homogeneous disease Example: Lebrikizumab in Asthma We strive to characterize the dominant causal factors in subsets of a heterogeneous disease and tailor the treatment to this well-defined subset 7 Our approach to drug development Develop best-in-disease treatments Develop clinically Target Product Profile is defined before the drug differentiated candidate enters clinical development based on products unmet medical need Set high efficacy Clinical trials are designed with ambitious end points hurdles to identify promising leads early Utilize biomarker Proof of concept studies are designed to show hypothesis remarkable efficacy in a target subpopulation Technical review is performed on on-going bases to Adjust strategy as identify potential issues and reassess the probability appropriate of success 8 gRED Development Portfolio 39 NMEs from Early development to Phase 2 Early Development Phase 1 Phase 2 NME AKT inh (GDC-0068) Anti-EGFL7 NME Anti-angiogenic Anti-HER3/EGFR NME Anti-PD-L1 PI3K inh (GDC-0941) NME Anti-CD22 ADC PI3K/mTOR inh(GDC-0980) NME Anti-STEAP1 ADC Pateclizumab (Anti-LTα) NME Antibody Drug Conjugate Quilizumab(Anti-M1 prime) NME Antibody Drug Conjugate Etrolizumab (rhuMab β7) Antibody Drug Conjugate Rontalizumab (a-IFNα) Antibody Drug Conjugate Crenezumab (Anti-Aβ) Antibody Drug Conjugate Anti-Factor D Antibody Drug Conjugate Anti-oxLDL Bcl-2 inh (GDC-0199) Anti-PCSK9 ChK-1 inh (GDC-0425) ChK-1 inh (GDC-0575) Oncology MEK inh (GDC-0973) Immunology MEK inh (GDC-0623) Neuroscience PI3K inh (GDC-0032) Ophthalmology PI3K inh (GDC-0084) Metabolism Anti-IL17 Infectious Diseases NME 9 Status as of June 30th, 2012 Collaborations with Roche diagnostics Over half of the NMEs are developed with CDx Early Development Phase 1 Phase 2 NME AKT inh (GDC-0068) Anti-EGFL7 NME Anti-angiogenic Anti-HER3/EGFR NME Anti-PD-L1 PI3K inh (GDC-0941) NME Anti-CD22 ADC PI3K/mTOR inh(GDC-0980) NME Anti-STEAP1 ADC Pateclizumab (Anti-LTα) NME Antibody Drug Conjugate Anti-M1 prime NME Antibody Drug Conjugate Etrolizumab (rhuMab β7) Antibody Drug Conjugate Rontalizumab (a-IFNα) Antibody Drug Conjugate Crenezumab (Anti-Aβ) Antibody Drug Conjugate Anti-Factor D Antibody Drug Conjugate Anti-oxLDL Bcl-2 inh (GDC-0199) Anti-PCSK9 ChK-1 inh (GDC-0425) ChK-1 inh (GDC-0575) MEK inh (GDC-0973) MEK inh (GDC-0623) With Companion Dx* PI3K inh (GDC-0032) Roche Tissue Diagnostics/Ventana Roche Molecular Diagnostics PI3K inh (GDC-0084) Anti-IL17 Roche Professional Diagnostics NME 10 Legend conveys investment with CDx assay development partner and does not reflect all Dx activities. Includes both initiated and (near-term) planned collaborations. Major trends in gRED portfolio Progress in understanding disease biology and new antibody technologies have re-shaped our portfolio We are pursuing targets outside oncology • 10 NMEs in other disease areas – Immunology, Neuroscience, Metabolism and Infectious Diseases We have built up a strong small molecules division • 10 small molecules are currently in clinical development We are exploring rational combinations to improve outcomes in oncology • Over 10 combinations of investigational products currently in clinic Extensive portfolio of antibody drug conjugates (ADCs) • 8 ADCs in clinical development for up to 10 oncology indications Novel antibody technologies • Bispecific and dual action antibodies may provide additional benefit in various diseases 11 gRED: Highlights with focus on Immunology Andrew Chan, Senior Vice President gRED Research Biology Oncology Immunology Antibody Drug Conjugates (ADCs) Extensive pipeline of ADCs for oncology indications Early Stage Late Stage Early Key Phase I/II Phase III Research Research Development Breast AML ESR ESR LSR Early Dev Anti-CD22 T-DM1 Melanoma ESR ESR LSR RG7596 Colon ESR ESR LSR Anti-STEAP1 Lung ESR RG7458 Multiple ESR RG7598 Myeloma Ovarian ESR RG7599 Prostate ESR RG7600 Pancreatic ESR RG7636 NHL ESR Diagnostics 3 As of July 25th, 2012 Solid tumor ADC 1 Confirmed partial response in ovarian cancer Baseline After 4 cycles Zoom • 60 year old woman with Ovarian Cancer following 7 prior therapies • Post cycle 2: partial response (-37.5%), Post cycle 4: confirmed PR (-51%) • Continues on study as of cycle 9 4 In collaboration with Seattle Genetics Solid tumor ADC 2 Confirmed partial response in ovarian cancer Baseline After 4 cycles 1500 1374 1250 1000 750 CA125* 500 28 250 0 -15 0 15 30 45 60 75 90 105 Study Day Cycle # 12 34 *Normal CA125: <36 Delay in Cycle 3 due to unplanned study hold • 66 year old woman with Ovarian Cancer following 3 different chemo regimens • Confirmed radiographic partial response • Serum CA125 tumor marker 1374 28 5 In collaboration with Seattle Genetics Solid Tumor ADC 3 Confirmed partial response in lung cancer Baseline After 4 cycles RECIST 34% • 73 year old woman with poorly differentiated non-small cell lung cancer • Previously treated with chemotherapy and erlotinib • Currently on study as of Cycle 6 6 In collaboration with Seattle Genetics Antibody Drug Conjugates (ADCs) Summary • Positioned well to advance largest industry platform of ADCs for all cancers • 9 ADCs in the clinic and 1 ADC in Early Development – Early signs of clinical activity in many Phase 1 programs in both hematologic and solid cancers – Two Phase 2’s to be initiated in 2012 and three potential Phase 2’s in 2013 • All solid tumor ADCs have accompanying diagnostics to identify appropriate patient population 7 Oncology Immunology gRED Immunology Understanding disease biology to benefit patients • Vision – Develop “best-in-disease” therapies to permit patients to live normal lives • Strategy – Discover major biological pathways that drive disease in patient subsets – Identify patient subsets that preferentially respond to targeted therapeutics – Develop ‘best-in-disease’ targeted therapies with head-to-head clinical trials against standard of care therapies for patient subsets 9 gRED Immunology Disease Area Targets Asthma Inflammatory Bowel Disease 1.5 million patients poorly controlled Prevalence up to 0.5% 1.5% of all ER visits and hospitalizations Almost $2B/yr in medical costs ~4000 deaths/yr Very poor sustained response to SOC Rheumatoid Arthritis Idiopathic Pulmonary Fibrosis Up to 1% of population affected Progressive fatal disease
Load more

Recommended publications
  • Recent Advances in Inflammatory Bowel Disease: Mucosal Immune
    Recent advances in basic science Recent advances in inflammatory bowel disease: Gut: first published as 10.1136/gutjnl-2012-303955 on 8 October 2013. Downloaded from mucosal immune cells in intestinal inflammation M Zaeem Cader,1,2 Arthur Kaser1 1Department of Medicine, ABSTRACT Recent years have seen a rapid and exciting Division of Gastroenterology & The intestine and its immune system have evolved to expansion in our understanding of the mucosal Hepatology, University of Cambridge, Addenbrooke’s meet the extraordinary task of maintaining tolerance to immune system with novel insights into environ- Hospital, Cambridge, UK the largest, most complex and diverse microbial mental influences of diet and the microbiota; the 2Wellcome Trust PhD commensal habitat, while meticulously attacking and convergence and integration of fundamental cellu- Programme for Clinicians, containing even minute numbers of occasionally lar processes such as autophagy, microbial sensing Cambridge Institute for incoming pathogens. While our understanding is still far and endoplasmic reticulum (ER) stress; as well as Medical Research, School of Clinical Medicine, University of from complete, recent studies have provided exciting the discovery of new cell types, for example innate Cambridge, Cambridge, UK novel insights into the complex interplay of the many lymphoid cells (ILCs). distinct intestinal immune cell types as well as the The gut is unlike the systemic immune system in Correspondence to discovery of entirely new cell subsets. These studies have several respects and much of the extensive reper- Dr Arthur Kaser, Department of Medicine, Division of also revealed how proper development and function of toire of immune cells and their characteristics are Gastroenterology and the intestinal immune system is dependent on its specific indeed unique to the intestine.
    [Show full text]
  • Classification Decisions Taken by the Harmonized System Committee from the 47Th to 60Th Sessions (2011
    CLASSIFICATION DECISIONS TAKEN BY THE HARMONIZED SYSTEM COMMITTEE FROM THE 47TH TO 60TH SESSIONS (2011 - 2018) WORLD CUSTOMS ORGANIZATION Rue du Marché 30 B-1210 Brussels Belgium November 2011 Copyright © 2011 World Customs Organization. All rights reserved. Requests and inquiries concerning translation, reproduction and adaptation rights should be addressed to [email protected]. D/2011/0448/25 The following list contains the classification decisions (other than those subject to a reservation) taken by the Harmonized System Committee ( 47th Session – March 2011) on specific products, together with their related Harmonized System code numbers and, in certain cases, the classification rationale. Advice Parties seeking to import or export merchandise covered by a decision are advised to verify the implementation of the decision by the importing or exporting country, as the case may be. HS codes Classification No Product description Classification considered rationale 1. Preparation, in the form of a powder, consisting of 92 % sugar, 6 % 2106.90 GRIs 1 and 6 black currant powder, anticaking agent, citric acid and black currant flavouring, put up for retail sale in 32-gram sachets, intended to be consumed as a beverage after mixing with hot water. 2. Vanutide cridificar (INN List 100). 3002.20 3. Certain INN products. Chapters 28, 29 (See “INN List 101” at the end of this publication.) and 30 4. Certain INN products. Chapters 13, 29 (See “INN List 102” at the end of this publication.) and 30 5. Certain INN products. Chapters 28, 29, (See “INN List 103” at the end of this publication.) 30, 35 and 39 6. Re-classification of INN products.
    [Show full text]
  • HY 2021 Results
    Roche HY 2021 results Basel, 22 July 2021 This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as ‘believes’, ‘expects’, ‘anticipates’, ‘projects’, ‘intends’, ‘should’, ‘seeks’, ‘estimates’, ‘future’ or similar expressions or by discussion of, among other things, strategy, goals, plans or intentions. Various factors may cause actual results to differ materially in the future from those reflected in forward-looking statements contained in this presentation, among others: 1 pricing and product initiatives of competitors; 2 legislative and regulatory developments and economic conditions; 3 delay or inability in obtaining regulatory approvals or bringing products to market; 4 fluctuations in currency exchange rates and general financial market conditions; 5 uncertainties in the discovery, development or marketing of new products or new uses of existing products, including without limitation negative results of clinical trials or research projects, unexpected side-effects of pipeline or marketed products; 6 increased government pricing pressures; 7 interruptions in production; 8 loss of or inability to obtain adequate protection for intellectual property rights; 9 litigation; 10 loss of key executives or other employees; and 11 adverse publicity and news coverage. Any statements regarding earnings per share growth is not a profit forecast and should not be interpreted to mean that Roche’s earnings or earnings per share for this year or any subsequent period will necessarily match or exceed the historical published earnings or earnings per share of Roche. For marketed products discussed in this presentation, please see full prescribing information on our website www.roche.com All mentioned trademarks are legally protected.
    [Show full text]
  • Looking for Therapeutic Antibodies in Next Generation Sequencing Repositories
    bioRxiv preprint doi: https://doi.org/10.1101/572958; this version posted March 10, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license. Title: Looking for Therapeutic Antibodies in Next Generation Sequencing Repositories. Authors: Konrad Krawczyk1*, Matthew Raybould2, Aleksandr Kovaltsuk2, Charlotte M. Deane2 1 NaturalAntibody, Hamburg, Germany 2 Oxford University Department of Statistics, Oxford, UK *Correspondence to [email protected] Abstract: Recently it has become possible to query the great diversity of natural antibody repertoires using Next Generation Sequencing (NGS). These methods are capable of producing millions of sequences in a single experiment. Here we compare Clinical Stage Therapeutic antibodies to the ~1b sequences from 60 independent sequencing studies in the Observed Antibody Space Database. Of the 242 post Phase I antibodies, we find 16 with sequence identity matches of 95% or better for both heavy and light chains. There are also 54 perfect matches to therapeutic CDR-H3 regions in the NGS outputs, suggesting a nontrivial amount of convergence between naturally observed sequences and those developed artificially. This has potential implications for both the discovery of antibody therapeutics and the legal protection of commercial antibodies. Introduction Antibodies are proteins in jawed vertebrates that recognize noxious molecules (antigens) for elimination. An organism expresses millions of diverse antibodies to increase the chances that some of them will be able to bind the foreign antigen, initiating the adaptive immune response.
    [Show full text]
  • Immunfarmakológia Immunfarmakológia
    Gergely: Immunfarmakológia Immunfarmakológia Prof Gergely Péter Az immunpatológiai betegségek döntő többsége gyulladásos, és ennek következtében általában szövetpusztulással járó betegség, melyben – jelenleg – a terápia alapvetően a gyulladás csökkentésére és/vagy megszűntetésére irányul. Vannak kizárólag gyulladásgátló gyógyszereink és vannak olyanok, amelyek az immunreakció(k) bénításával (=immunszuppresszió révén) vagy emellett vezetnek a gyulladás mérsékléséhez. Mind szerkezetileg, mind hatástanilag igen sokféle csoportba oszthatók, az alábbi felosztás elsősorban didaktikus célokat szolgál. 1. Nem-szteroid gyulladásgátlók (‘nonsteroidal antiinflammatory drugs’ NSAID) 2. Kortikoszteroidok 3. Allergia-elleni szerek (antiallergikumok) 4. Sejtoszlás-gátlók (citosztatikumok) 5. Nem citosztatikus hatású immunszuppresszív szerek 6. Egyéb gyulladásgátlók és immunmoduláns szerek 7. Biológiai terápia 1. Nem-szteroid gyulladásgátlók (NSAID) Ezeket a vegyületeket, melyek őse a szalicilsav (jelenleg, mint acetilszalicilsav ‘aszpirin’ használatos), igen kiterjedten alkalmazzák a reumatológiában, az onkológiában és az orvostudomány szinte minden ágában, ahol fájdalom- és lázcsillapításra van szükség. Egyes felmérések szerint a betegek egy ötöde szed valamilyen NSAID készítményt. Szerkezetük alapján a készítményeket több csoportba sorolhatjuk: szalicilátok (pl. acetilszalicilsav) pyrazolidinek (pl. fenilbutazon) ecetsav származékok (pl. indometacin) fenoxiecetsav származékok (pl. diclofenac, aceclofenac)) oxicamok (pl. piroxicam, meloxicam) propionsav
    [Show full text]
  • The Two Tontti Tudiul Lui Hi Ha Unit
    THETWO TONTTI USTUDIUL 20170267753A1 LUI HI HA UNIT ( 19) United States (12 ) Patent Application Publication (10 ) Pub. No. : US 2017 /0267753 A1 Ehrenpreis (43 ) Pub . Date : Sep . 21 , 2017 ( 54 ) COMBINATION THERAPY FOR (52 ) U .S . CI. CO - ADMINISTRATION OF MONOCLONAL CPC .. .. CO7K 16 / 241 ( 2013 .01 ) ; A61K 39 / 3955 ANTIBODIES ( 2013 .01 ) ; A61K 31 /4706 ( 2013 .01 ) ; A61K 31 / 165 ( 2013 .01 ) ; CO7K 2317 /21 (2013 . 01 ) ; (71 ) Applicant: Eli D Ehrenpreis , Skokie , IL (US ) CO7K 2317/ 24 ( 2013. 01 ) ; A61K 2039/ 505 ( 2013 .01 ) (72 ) Inventor : Eli D Ehrenpreis, Skokie , IL (US ) (57 ) ABSTRACT Disclosed are methods for enhancing the efficacy of mono (21 ) Appl. No. : 15 /605 ,212 clonal antibody therapy , which entails co - administering a therapeutic monoclonal antibody , or a functional fragment (22 ) Filed : May 25 , 2017 thereof, and an effective amount of colchicine or hydroxy chloroquine , or a combination thereof, to a patient in need Related U . S . Application Data thereof . Also disclosed are methods of prolonging or increasing the time a monoclonal antibody remains in the (63 ) Continuation - in - part of application No . 14 / 947 , 193 , circulation of a patient, which entails co - administering a filed on Nov. 20 , 2015 . therapeutic monoclonal antibody , or a functional fragment ( 60 ) Provisional application No . 62/ 082, 682 , filed on Nov . of the monoclonal antibody , and an effective amount of 21 , 2014 . colchicine or hydroxychloroquine , or a combination thereof, to a patient in need thereof, wherein the time themonoclonal antibody remains in the circulation ( e . g . , blood serum ) of the Publication Classification patient is increased relative to the same regimen of admin (51 ) Int .
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2017/0172932 A1 Peyman (43) Pub
    US 20170172932A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2017/0172932 A1 Peyman (43) Pub. Date: Jun. 22, 2017 (54) EARLY CANCER DETECTION AND A 6LX 39/395 (2006.01) ENHANCED IMMUNOTHERAPY A61R 4I/00 (2006.01) (52) U.S. Cl. (71) Applicant: Gholam A. Peyman, Sun City, AZ CPC .......... A61K 9/50 (2013.01); A61K 39/39558 (US) (2013.01); A61K 4I/0052 (2013.01); A61 K 48/00 (2013.01); A61K 35/17 (2013.01); A61 K (72) Inventor: sham A. Peyman, Sun City, AZ 35/15 (2013.01); A61K 2035/124 (2013.01) (21) Appl. No.: 15/143,981 (57) ABSTRACT (22) Filed: May 2, 2016 A method of therapy for a tumor or other pathology by administering a combination of thermotherapy and immu Related U.S. Application Data notherapy optionally combined with gene delivery. The combination therapy beneficially treats the tumor and pre (63) Continuation-in-part of application No. 14/976,321, vents tumor recurrence, either locally or at a different site, by filed on Dec. 21, 2015. boosting the patient’s immune response both at the time or original therapy and/or for later therapy. With respect to Publication Classification gene delivery, the inventive method may be used in cancer (51) Int. Cl. therapy, but is not limited to such use; it will be appreciated A 6LX 9/50 (2006.01) that the inventive method may be used for gene delivery in A6 IK 35/5 (2006.01) general. The controlled and precise application of thermal A6 IK 4.8/00 (2006.01) energy enhances gene transfer to any cell, whether the cell A 6LX 35/7 (2006.01) is a neoplastic cell, a pre-neoplastic cell, or a normal cell.
    [Show full text]
  • Novel Therapies for Eosinophilic Disorders
    Novel Therapies for Eosinophilic Disorders Bruce S. Bochner, MD KEYWORDS Eosinophil Therapies Antibodies Targets Pharmacology Biomarkers KEY POINTS A sizable unmet need exists for new, safe, selective, and effective treatments for eosinophil-associated diseases, such as hypereosinophilic syndrome, eosinophilic gastrointestinal disorders, nasal polyposis, and severe asthma. An improved panel of biomarkers to help guide diagnosis, treatment, and assessment of disease activity is also needed. An impressive array of novel therapeutic agents, including small molecules and biologics, that directly or indirectly target eosinophils and eosinophilic inflammation are undergoing controlled clinical trials, with many already showing promising results. A large list of additional eosinophil-related potential therapeutic targets remains to be pursued, including cell surface structures, soluble proteins that influence eosinophil biology, and eosinophil-derived mediators that have the potential to contribute adversely to disease pathophysiology. INTRODUCTION Eosinophilic disorders, also referred to as eosinophil-associated diseases, consist of a range of infrequent conditions affecting virtually any body compartment and organ.1 The most commonly affected areas include the bone marrow, blood, mucosal sur- faces, and skin, often with immense disease- and treatment-related morbidity, Disclosure Statement: Dr Bochner’s research efforts are supported by grants AI072265, AI097073 and HL107151 from the National Institutes of Health. He has current or recent consul- ting or scientific advisory board arrangements with, or has received honoraria from, Sanofi-A- ventis, Pfizer, Svelte Medical Systems, Biogen Idec, TEVA, and Allakos, Inc. and owns stock in Allakos, Inc. and Glycomimetics, Inc. He receives publication-related royalty payments from Elsevier and UpToDate and is a coinventor on existing and pending Siglec-8-related patents and, thus, may be entitled to a share of future royalties received by Johns Hopkins University on the potential sales of such products.
    [Show full text]
  • WO 2016/176089 Al 3 November 2016 (03.11.2016) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2016/176089 Al 3 November 2016 (03.11.2016) P O P C T (51) International Patent Classification: BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, A01N 43/00 (2006.01) A61K 31/33 (2006.01) DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, (21) International Application Number: KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, PCT/US2016/028383 MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, (22) International Filing Date: PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, 20 April 2016 (20.04.2016) SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (25) Filing Language: English (84) Designated States (unless otherwise indicated, for every (26) Publication Language: English kind of regional protection available): ARIPO (BW, GH, (30) Priority Data: GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, 62/154,426 29 April 2015 (29.04.2015) US TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, (71) Applicant: KARDIATONOS, INC. [US/US]; 4909 DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, Lapeer Road, Metamora, Michigan 48455 (US).
    [Show full text]
  • Biologics in Asthma
    Biologics in Asthma: Present andPresenter Future of Flavia Hoyte,Reproduction MD Associate Professorfor of Medicine FellowshipProperty Training Program Director DivisionNot of Allergy and Immunology National Jewish Health and University of Colorado Disclosures Clinical investigator for GSK, TEVA, and Astra‐ Zeneca. Presenter of Reproduction for Property Not Learning objectives 1. Discuss current approaches to the management of moderate to severe asthma in adult patients. Presenter of 2. Describe new and emergingReproduction biologics for for the managementProperty of moderate to severe asthma. Not Asthma: A Highly Prevalent and Often Inadequately Controlled Disease 24+ million people in the US have asthma.1 17.72 million adults have asthma.Presenter1 of Reproduction 8.86 million adults havefor inadequately 39% of adults with Propertycontrolled asthma.2 1.33 million adults active asthma use Not have inadequately long‐term control controlled asthma medications.3 with eosinophilia.4 1. Centers for Disease Control and Prevention (CDC). Most Recent Asthma Data (2014 data). Accessed June 2016. 2. CDC. Uncontrolled asthma among persons with current asthma. Accessed June 2016. 3. CDC. Use of long‐term control medication among persons with active asthma. Accessed June 2016. 4. McGrath KW et al. Am J Respir Crit Care Med. 2012;185:612‐619. Paradigm Shift to a More Personalized Approach to Asthma Therapy Presenter of Reproduction for Property Not Dunn RM and Wechsler ME. Clinical Pharmacology and Therapeutics 2015; 97(1): 55‐65. Immunopathology of Asthma Presenter of Reproduction for Property Not Pelaia G, et al. Mediators Inflamm 2015:879783. doi: 10.1155/2015/879783. Epub 2015 Mar 23. Presenter of Reproduction for Property Not Katial et al.
    [Show full text]
  • Roche Investor Presentation Oppenheimer 23Rd Annual
    Roche: Oppenheimer 23rd Annual Healthcare Conference Thomas Kudsk Larsen, Head of Investor Relations North America, New York, 12 December 2012 Forward-looking statements This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as ‘believes’, ‘expects’, ‘anticipates’, ‘projects’, ‘intends’, ‘should’, ‘seeks’, ‘estimates’, ‘future’ or similar expressions or by discussion of, among other things, strategy, goals, plans or intentions. Various factors may cause actual results to differ materially in the future from those reflected in forward-looking statements contained in this presentation, among others: 1. pricing and product initiatives of competitors; 2. legislative and regulatory developments and economic conditions; 3. delay or inability in obtaining regulatory approvals or bringing products to market; 4. fluctuations in currency exchange rates and general financial market conditions; 5. uncertainties in the discovery, development or marketing of new products or new uses of existing products, including without limitation negative results of clinical trials or research projects, unexpected side-effects of pipeline or marketed products; 6. increased government pricing pressures; 7. interruptions in production; 8. loss of or inability to obtain adequate protection for intellectual property rights; 9. Litigation; 10. loss of key executives or other employees; and 11. adverse publicity and news coverage. Any statements regarding earnings per share growth is not a profit forecast and should not be interpreted to mean that Roche’s earnings or earnings per share for this year or any subsequent period will necessarily match or exceed the historical published earnings or earnings per share of Roche. For marketed products discussed in this presentation, please see full prescribing information on our website2 www.roche.com.
    [Show full text]
  • Minutes PDCO 25-28 February 2020
    26 February 2020 EMA/PDCO/104692/2020 Inspections, Human Medicines Pharmacovigilance and Committees Division Paediatric Committee (PDCO) Minutes for the meeting on 25-28 February 2020 Chair: Koenraad Norga – Vice-Chair: Sabine Scherer Disclaimers Some of the information contained in these minutes is considered commercially confidential or sensitive and therefore not disclosed. With regard to intended therapeutic indications or procedure scopes listed against products, it must be noted that these may not reflect the full wording proposed by applicants and may also vary during the course of the review. Additional details on some of these procedures will be published in the PDCO Committee meeting reports (after the PDCO Opinion is adopted), and on the Opinions and decisions on paediatric investigation plans webpage (after the EMA Decision is issued). Of note, this set of minutes is a working document primarily designed for PDCO members and the work the Committee undertakes. Further information with relevant explanatory notes can be found at the end of this document. Note on access to documents Some documents mentioned in the minutes cannot be released at present following a request for access to documents within the framework of Regulation (EC) No 1049/2001 as they are subject to on- going procedures for which a final decision has not yet been adopted. They will become public when adopted or considered public according to the principles stated in the Agency policy on access to documents (EMA/127362/2006). Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 An agency of the European Union © European Medicines Agency, 2020.
    [Show full text]